Voyager Therapeutics, Inc. (NASDAQ:VYGR) Shares Sold by Cornercap Investment Counsel Inc.

Cornercap Investment Counsel Inc. decreased its holdings in Voyager Therapeutics, Inc. (NASDAQ:VYGR) by 52.4% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 10,937 shares of the company’s stock after selling 12,039 shares during the quarter. Cornercap Investment Counsel Inc.’s holdings in Voyager Therapeutics were worth $64,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of VYGR. Vanguard Group Inc. increased its position in shares of Voyager Therapeutics by 27.8% in the first quarter. Vanguard Group Inc. now owns 3,231,698 shares of the company’s stock valued at $30,087,000 after buying an additional 702,030 shares in the last quarter. Great Point Partners LLC purchased a new stake in Voyager Therapeutics in the 2nd quarter worth $12,668,000. Armistice Capital LLC raised its position in Voyager Therapeutics by 11.3% during the second quarter. Armistice Capital LLC now owns 5,200,000 shares of the company’s stock worth $41,132,000 after acquiring an additional 528,000 shares during the period. Price T Rowe Associates Inc. MD lifted its holdings in Voyager Therapeutics by 3.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 1,041,930 shares of the company’s stock valued at $9,702,000 after purchasing an additional 37,144 shares in the last quarter. Finally, Patriot Financial Group Insurance Agency LLC acquired a new stake in shares of Voyager Therapeutics in the second quarter valued at about $1,012,000. Hedge funds and other institutional investors own 48.03% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $30.00 price target on shares of Voyager Therapeutics in a research note on Thursday, November 14th. StockNews.com raised Voyager Therapeutics from a “hold” rating to a “buy” rating in a research note on Monday. Leerink Partners initiated coverage on Voyager Therapeutics in a research note on Wednesday, October 16th. They issued an “outperform” rating and a $15.00 price objective for the company. Canaccord Genuity Group reaffirmed a “buy” rating and set a $14.00 target price on shares of Voyager Therapeutics in a research note on Thursday, November 14th. Finally, Leerink Partnrs upgraded shares of Voyager Therapeutics to a “strong-buy” rating in a research report on Wednesday, October 16th. One equities research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Voyager Therapeutics currently has an average rating of “Buy” and a consensus target price of $17.00.

Insider Activity

In other Voyager Therapeutics news, insider Sandell Jacquelyn Fahey sold 5,999 shares of Voyager Therapeutics stock in a transaction on Wednesday, October 2nd. The stock was sold at an average price of $5.82, for a total value of $34,914.18. Following the sale, the insider now owns 86,001 shares in the company, valued at $500,525.82. The trade was a 6.52 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 4.53% of the company’s stock.

Voyager Therapeutics Stock Down 4.5 %

Shares of NASDAQ:VYGR opened at $5.39 on Tuesday. Voyager Therapeutics, Inc. has a 52-week low of $5.38 and a 52-week high of $11.72. The stock has a market cap of $294.18 million, a P/E ratio of 7.59 and a beta of 0.89. The business has a fifty day moving average of $6.62 and a two-hundred day moving average of $7.49.

Voyager Therapeutics (NASDAQ:VYGR) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.29. Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. The firm had revenue of $24.63 million during the quarter, compared to analyst estimates of $12.63 million. During the same quarter in the prior year, the firm posted ($0.59) earnings per share. On average, equities analysts anticipate that Voyager Therapeutics, Inc. will post -1.12 earnings per share for the current year.

Voyager Therapeutics Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.